{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:41:34Z","timestamp":1791024094550,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes for Health Research (CIHR)","doi-asserted-by":"crossref","award":["CTP-82944"],"award-info":[{"award-number":["CTP-82944"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes for Health Research (CIHR)","doi-asserted-by":"crossref","award":["MOP-119487"],"award-info":[{"award-number":["MOP-119487"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"US Lysosomal Storage Disease Research Consortium"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.ymgme.2012.06.007","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T15:36:26Z","timestamp":1340120186000},"page":"203-212","source":"Crossref","is-referenced-by-count":43,"title":["Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy"],"prefix":"10.1016","volume":"107","author":[{"given":"Brigitte A.","family":"Rigat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Tropak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Buttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Crushell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Benedict","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don J.","family":"Mahuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2012.06.007_bb0005","series-title":"The On-Line Metabolic Basis of Inherited Disease","first-page":"1","article-title":"\u03b2-Galactosidase deficiency (\u03b2-galactosidase): GM1 gangliosidosis and Morquio B disease","author":"Suzuki","year":"2008"},{"key":"10.1016\/j.ymgme.2012.06.007_bb0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000112332","article-title":"Partial enzyme deficiencies: residual activities and the development of neurological disorders","volume":"6","author":"Conzelmann","year":"1983","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/B:BOLI.0000031101.12838.c6","article-title":"Enzyme replacement and enhancement therapies for lysosomal diseases","volume":"27","author":"Desnick","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0020","first-page":"349","article-title":"Gene therapy for the lysosomal storage disorders","volume":"4","author":"Cabrera-Salazar","year":"2002","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/13543784.12.2.273","article-title":"Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher Disease type 1","volume":"12","author":"Pastores","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymgme.2012.06.007_bb0030","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","article-title":"Gastrointestinal disturbances and their management in miglustat-treated patients","volume":"34","author":"Belmatoug","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0035","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1111\/j.1742-4658.2007.06040.x","article-title":"Lending a helping hand, screening chemical libraries for compounds that enhance beta-hexosaminidase A activity in GM2 gangliosidosis cells","volume":"274","author":"Tropak","year":"2007","journal-title":"FEBS J."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0040","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher Disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0045","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2004.05293.x","article-title":"Lysosomal storage disorders","volume":"128","author":"Vellodi","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2010.09.004","article-title":"An open-label Phase I\/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)","volume":"102","author":"Clarke","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0055","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.ymgme.2012.06.007_bb0060","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher Disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0065","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/BF00223869","article-title":"Alpha-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins","volume":"95","author":"Okumiya","year":"1995","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0070","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1006\/bbrc.1996.0486","article-title":"Aggregation of the inactive form of human alpha-galactosidase in the endoplasmic reticulum","volume":"220","author":"Ishii","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"Pt 3","key":"10.1016\/j.ymgme.2012.06.007_bb0075","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/0264-6021:3480621","article-title":"Characterization of beta-galactosidase mutations Asp332\u2013>Asn and Arg148\u2013>Ser, and a polymorphism, Ser532\u2013>Gly, in a case of GM1 gangliosidosis","volume":"348","author":"Zhang","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0080","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1203\/00006450-200212000-00004","article-title":"Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking","volume":"52","author":"Perlmutter","year":"2002","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/5.1.1","article-title":"Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases","volume":"5","author":"Phaneuf","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism","volume":"11","author":"Sango","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0095","first-page":"497","article-title":"Beta-hexosaminidase isozymes from cells co-transfected with alpha and beta cDNA constructs: analysis of alpha subunit missense mutation associated with the adult form of Tay-Sachs disease","volume":"53","author":"Brown","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0100","doi-asserted-by":"crossref","first-page":"23681","DOI":"10.1016\/S0021-9258(17)31569-7","article-title":"Overexpression rescues the mutant phenotype of L176F mutation causing beta-glucuronidase deficiency mucopolysaccharidosis in two Mennonite siblings","volume":"269","author":"Wu","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0105","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/hmg\/6.2.205","article-title":"Generalized CNS disease and massive GM1 ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase","volume":"6","author":"Hahn","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ana.21284","article-title":"Chemical chaperone therapy: clinical effect in murine G(M1)-gangliosidosis","volume":"62","author":"Suzuki","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2012.02.012","article-title":"Therapeutic chaperone effect of N-Octyl 4-Epi-beta-valienamine on murine G(M1)-gangliosidosis","volume":"106","author":"Suzuki","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0125","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.braindev.2006.02.002","article-title":"Fibroblast screening for chaperone therapy in beta-galactosidosis","volume":"28","author":"Iwasaki","year":"2006","journal-title":"Brain Dev."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0130","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1023\/A:1021280007739","article-title":"A novel mutation in the gene for canine acid beta-galactosidase that causes GM1 gangliosidosis in Shiba dogs","volume":"25","author":"Yamato","year":"2002","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0135","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1292\/jvms.65.213","article-title":"Clinical and clinico-pathologic characteristics of Shiba dogs with a deficiency of lysosomal acid beta-galactosidase: a canine model of human GM1 gangliosidosis","volume":"65","author":"Yamato","year":"2003","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0140","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2008.02.004","article-title":"Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis","volume":"94","author":"Martin","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0145","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1089\/gte.2005.9.126","article-title":"The Arg482His mutation in the beta-galactosidase gene is responsible for a high frequency of GM1 gangliosidosis carriers in a Cypriot village","volume":"9","author":"Georgiou","year":"2005","journal-title":"Genet. Test."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0150","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1074\/jbc.M111.293795","article-title":"Crystal structure of human beta-galactosidase: the structural basis of GM1 gangliosidosis and Morquio B diseases","volume":"287","author":"Ohto","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0155","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1126\/science.174.4011.838","article-title":"Neuronal GM1 gangliosidosis in a Siamese cat with beta-galactosidase deficiency","volume":"174","author":"Baker","year":"1971","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2012.06.007_bb0160","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1098\/rstb.2003.1278","article-title":"Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders","volume":"358","author":"Butters","year":"2003","journal-title":"Philos. Trans. R. Soc. Lond. B"},{"key":"10.1016\/j.ymgme.2012.06.007_bb0165","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0006-2952(99)00384-6","article-title":"N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo","volume":"59","author":"Andersson","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0170","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1016\/S0021-9258(17)37202-2","article-title":"N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis","volume":"269","author":"Platt","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0175","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0180","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1139\/o80-038","article-title":"The subunit and polypeptide structure of hexosaminidases from human placenta","volume":"58","author":"Mahuran","year":"1980","journal-title":"Can. J. Biochem."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0185","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1042\/bj2850827","article-title":"Human placental beta-galactosidase: characterization of the dimer and complex forms of the enzyme","volume":"285","author":"Hubbes","year":"1992","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0190","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ymgme.2008.12.008","article-title":"Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells","volume":"96","author":"Rigat","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0195","doi-asserted-by":"crossref","first-page":"e24951","DOI":"10.1371\/journal.pone.0024951","article-title":"Characterization of the biosynthesis, processing and kinetic mechanism of action of the enzyme deficient in mucopolysaccharidosis IIIC","volume":"6","author":"Fan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2012.06.007_bb0200","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0387-7604(01)00216-9","article-title":"Galactonojirimycin derivatives restore mutant human beta-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouse","volume":"23","author":"Tominaga","year":"2001","journal-title":"Brain Dev."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0205","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2008.12.017","article-title":"Molecular interaction of imino sugars with human alpha-galactosidase: insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease","volume":"96","author":"Sugawara","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0210","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10545-011-9409-2","article-title":"Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB1 alleles causing G(M1)-gangliosidosis and Morquio B disease","volume":"35","author":"Fantur","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0215","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ymgme.2010.03.019","article-title":"DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts","volume":"100","author":"Fantur","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0220","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/sj.gt.3302033","article-title":"Attenuation of ganglioside GM1 accumulation in the brain of GM1 gangliosidosis mice by neonatal intravenous gene transfer","volume":"10","author":"Takaura","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2012.06.007_bb0225","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF00220071","article-title":"A homozygous missense arginine to histidine substitution at position 482 of the beta-galactosidase in an Italian infantile GM1 gangliosidosis patient","volume":"90","author":"Mosna","year":"1992","journal-title":"Hum. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212002430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212002430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T23:20:24Z","timestamp":1642548024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719212002430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":45,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1096719212002430"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2012.06.007","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}